{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:40:58Z","timestamp":1774878058913,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clgc.2013.11.020","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T01:45:20Z","timestamp":1384393520000},"page":"241-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma"],"prefix":"10.1016","volume":"12","author":[{"given":"Rhonda L.","family":"Bitting","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia A.","family":"Creel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah Yenser","family":"Wood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert I.","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew B.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2013.11.020_bib1","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib2","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"26","author":"Burstein","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib3","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib4","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1200\/JCO.2007.13.9303","article-title":"Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer","volume":"26","author":"Socinski","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib7","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib10","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2013.11.020_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib12","doi-asserted-by":"crossref","first-page":"7068","DOI":"10.1158\/1078-0432.CCR-08-0260","article-title":"Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas","volume":"14","author":"Desjardins","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.11.020_bib13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.clgc.2013.11.020_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clgc.2013.11.020_bib16","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib18","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2013.11.020_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2013.11.020_bib20","first-page":"4819","article-title":"Effects of PTK787\/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model","volume":"60","author":"Drevs","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.11.020_bib21","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1200\/JCO.2003.08.092","volume":"21","author":"Morgan","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib22","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2005.09.034","article-title":"Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787\/ZK 222584 administered twice daily in patients with advanced cancer","volume":"23","author":"Thomas","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib23","first-page":"845","article-title":"A\u00a0phase I trial of vatalanib (PTK\/ZK) in combination with bevacizumab in patients with refractory and\/or advanced malignancies","volume":"9","author":"Jones","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/07357907.2011.568567","article-title":"A\u00a0phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies","volume":"29","author":"Spigel","year":"2011","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clgc.2013.11.020_bib25","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-08-0417","article-title":"Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787\/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma","volume":"14","author":"de Bazelaire","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.11.020_bib26","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","article-title":"Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma","volume":"29","author":"Hecht","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib27","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2010.29.5436","article-title":"Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787\/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2013.11.020_bib29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2174\/156800908786733513","article-title":"mTOR pathway and mTOR inhibitors as agents for cancer therapy","volume":"8","author":"Baldo","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clgc.2013.11.020_bib30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nm1337","article-title":"Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib31","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib32","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Garcia","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2013.11.020_bib33","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2013.11.020_bib34","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib36","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2013.11.020_bib37","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","article-title":"mTOR inhibitor RAD001 (everolimus) has antiangiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor","volume":"15","author":"Lane","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.11.020_bib38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00280-010-1307-z","article-title":"Everolimus and PTK\/ZK show synergistic growth inhibition in the orthotopic BL16\/BL6 murine melanoma model","volume":"67","author":"O'Reilly","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2013.11.020_bib39","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1053\/j.seminoncol.2006.06.001","article-title":"Molecular pathways in renal cell carcinoma\u2014rationale for targeted treatment","volume":"33","author":"Kim","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4161\/cbt.9.11.11805","article-title":"Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in\u00a0vivo","volume":"9","author":"Jaeger-Lansky","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clgc.2013.11.020_bib41","first-page":"299","article-title":"mTOR as a positive regulator of tumor cell responses to hypoxia","volume":"279","author":"Abraham","year":"2004","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.clgc.2013.11.020_bib42","doi-asserted-by":"crossref","first-page":"29655","DOI":"10.1074\/jbc.M212770200","article-title":"A\u00a0novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets","volume":"278","author":"Arsham","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clgc.2013.11.020_bib43","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1096\/fj.01-0658com","article-title":"Hypoxia enhances vascular cell proliferation and angiogenesis in\u00a0vitro via rapamycin (mTOR)-dependent signaling","author":"Humar","year":"2002","journal-title":"FASEB J"},{"key":"10.1016\/j.clgc.2013.11.020_bib44","doi-asserted-by":"crossref","first-page":"27975","DOI":"10.1074\/jbc.M204152200","article-title":"Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase\/target of rapamycin-dependent signaling pathway","volume":"277","author":"Treins","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clgc.2013.11.020_bib45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1101\/gad.14.4.391","article-title":"Loss of PTEN facilitates HIF-1-mediated gene expression","volume":"14","author":"Zundel","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.clgc.2013.11.020_bib46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2013.11.020_bib47","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib48","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/annonc\/mdl469","article-title":"A\u00a0phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787\/ZK 222584 (PTK\/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer","volume":"18","author":"Thomas","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma","volume":"7","author":"Patel","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2013.11.020_bib50","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/cncr.24234","article-title":"Combination targeted therapy in advanced renal cell carcinoma","volume":"115","author":"Sosman","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2013.11.020_bib51","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","article-title":"Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma","volume":"28","author":"Hainsworth","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib52","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.25931","article-title":"A\u00a0phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma","volume":"117","author":"Harzstark","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2013.11.020_bib53","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"25","author":"Fouladi","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","article-title":"Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells","volume":"64","author":"Boulay","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2013.11.020_bib55","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-10-0124","article-title":"A\u00a0pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2013.11.020_bib56","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2011.40.9631","article-title":"Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin","volume":"30","author":"Armstrong","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2013.11.020_bib57","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1158\/1078-0432.CCR-10-2918","article-title":"Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787\/ZK 222584 (vatalanib) antiangiogenic therapy","volume":"17","author":"Koukourakis","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313002917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767313002917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:23:09Z","timestamp":1761564189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767313002917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1558767313002917"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2013.11.020","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2013.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}